Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 8 Glioblastoma 7 Urinary Bladder Neoplasms 6 Breast Neoplasms 6 Oropharyngeal Neoplasms 5 Neoplasm Metastasis 5 Lung Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Carcinoma 5 Burkitt Lymphoma 5 Astrocytoma 5 Sarcoma 4 Squamous Cell Carcinoma of Head and Neck 3 Rhabdomyosarcoma, Embryonal 3 Pancreatic Neoplasms 3 Mouth Neoplasms 3 Laryngeal Neoplasms 3 Glioma 3 Esophageal Neoplasms 3 Adenocarcinoma of Lung 3 Triple Negative Breast Neoplasms 2 Sarcoma, Synovial 2 Sarcoma, Ewing 2 Rhabdomyosarcoma, Alveolar 2 Rhabdomyosarcoma 2 Rectal Neoplasms 2 Prostate Adenocarcinoma 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Melanoma 2

Interventions

Cyclophosphamide 9 fludarabine 7 Dexamethasone 7 pomalidomide 6 Rituximab 6 pembrolizumab 5 selinexor 4 obinutuzumab 4 glofitamab 4 Lenalidomide 4 daratumumab 3 belantamab mafodotin 3 Temozolomide 3 Gemcitabine 3 Etoposide 3 Bortezomib 3 zanubrutinib 2 venetoclax 2 tocilizumab 2 fludarabine phosphate 2 enzalutamide 2 cemiplimab 2 carfilzomib 2 abemaciclib 2 PF06821497 2 Mesna 2 Lisaftoclax 2 Injections 2 Immunotherapy, Adoptive 2 Granulocyte Colony-Stimulating Factor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Radiation × 30 days × Clear all

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡